Publications

Reviews

Kaddurah-Daouk R, Weinshilboum R; Pharmacometabolomics Research Network. Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.Clin Pharmacol Ther. 2015 Jul;98(1):71-5. doi: 10.1002/cpt.134. Epub 2015 Jun 4. PMID: 25871646

Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology. Clin Pharmacol Ther. 2013 Nov 5. doi: 10.1038/clpt.2013.217.

Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009 Jan;34(1):173-86. doi: 10.1038/npp.2008.174. PubMed PMID: 18843269.

Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009 Aug;35(2):165-76. doi: 10.1016/j.nbd.2009.02.019. Epub 2009 Mar 19. PubMed PMID: 19303440.

Kaddurah-Daouk R, Kristal BS, Weinshilboum RM.(2008). Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.

Variation of response to treatment

Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Zhu H, Mahmoudiandehkordi S, Neavin D, Louie G, Dunlop BW, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk R. Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Transl Psychiatry; 2019; 9(1): 173; doi:10.1038/s41398-019-0507-5

Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension (Dallas, Tex : 1979). 2016;68(3):621-9. Epub 2016/07/07. doi: 10.1161/hypertensionaha.116.07328. PubMed PMID: 27381900; PMCID: PMC4982802.

Rotroff DM, Oki NO, Liang X, Yee SW, Stocker SL, Corum DG, Meisner M, Fiehn O, Motsinger-Reif AA, Giacomini KM, Kaddurah-Daouk R. Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Frontiers in pharmacology. 2016;7:135. Epub 2016/07/06. doi: 10.3389/fphar.2016.00135. PubMed PMID: 27378919; PMCID: PMC4906013.

Rotroff DM, Corum DG, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets WC, Singh J, Salvadore G, Kaddurah-Daouk R. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Translational psychiatry. 2016;6(9):e894. Epub 2016/09/21. doi: 10.1038/tp.2016.145. PubMed PMID: 27648916; PMCID: PMC5048196.

Neavin D, Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics informs Pharmacogenomics. Metabolomics. 2016;12(7). Epub 2016/08/16. doi: 10.1007/s11306-016-1066-x. PubMed PMID: 27516730; PMCID: PMC4976774.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Molecular psychiatry. 2016; 21(12):1717-25. Epub 2016/02/24. doi: 10.1038/mp.2016.6. PubMed PMID: 26903268; PMCID: PMC5003027.

de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 2016;12(8):129. doi: 10.1007/s11306-016-1076-8.

Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, Brennan L, Wishart DS, Oresic M, Hankemeier T, Broadhurst DI, Lane AN, Suhre K, Kastenmuller G, Sumner SJ, Thiele I, Fiehn O, Kaddurah-Daouk R. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics. 2016; 12(10):149. Epub 2016/09/20. doi: 10.1007/s11306-016-1094-6. PubMed PMID: 27642271; PMCID: PMC5009152.

Wang Z, Maity A, Hsiao CK, Voora D, Kaddurah-Daouk R, Tzeng JY. Module-based association analysis for omics data with network structure. PLoS One. 2015;10(3):e0122309. Epub 2015/03/31. doi: 10.1371/journal.pone.0122309. PubMed PMID: 25822417; PMCID: PMC4378989.

Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Meisner M, Beitelshees AL, Fiehn O, Johnson JA, Elbadawi-Sidhu M, Frye RF, Gong Y, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk R. Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT: pharmacometrics & systems pharmacology. 2015;4(11):669-79. doi: 10.1002/psp4.12017. PubMed PMID: 26783503; PMCID: PMC4716583

Rasmussen HB, Bjerre D, Linnet K, Jurgens G, Dalhoff K, Stefansson H, Hankemeier T, Kaddurah-Daouk R, Taboureau O, Brunak S, Houmann T, Jeppesen P, Pagsberg AK, Plessen K, Dyrborg J, Hansen PR, Hansen PE, Hughes T, Werge T. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics. 2015;16(6):649-65. Epub 2015/04/22. doi: 10.2217/pgs.15.7. PubMed PMID: 25896426.

Ellero-Simatos S, Beitelshees AL, Lewis JP, Yerges-Armstrong LM, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. Journal of the American Heart Association. 2015;4(10):e002203. Epub 2015/10/28. doi: 10.1161/jaha.115.002203. PubMed PMID: 26504148; PMCID: PMC4845113.

Studies from Pharmacometabolomics Research Network- Applications of Metabolomics in Precision Medicine

Mood disorders

MahmoudianDehkordi S, Ahmed AT, Bhattacharyya S, Han X, Baillie RA, Arnold M, Skime MK, St. John-Williams L, Moseley MA, Thompson JW, Louie G, Riva-Posse P, Craighead WE, McDonald W, Krishnan R, Rush AJ, Frye MA, Dunlop BW, Weinshilboum RM, The Mood Disorders Precision Medicine Consortium (MDPMC), Kaddurah-Daouk R. Alterations in Acylcarnitines, Amines, and Lipids Inform about Mechanism of Action of Citalopram/Escitalopram in Major Depression. BioRxiv. 2020 Feb 10

Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Moseley MA, Thompson JW, Williams LSJ, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald WM, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, Dunlop BW, Millington DS, Rush AJ, Frye MA, Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord; 2020; 264:90-97. doi: 10.1016/j.jad.2019.11.122

Bhattacharyya S, Dunlop BW, Mahmoudiandehkordi S, Ahmed AT,  Louie G, Frye MA, Weinshilboum RM, Krishnan RR, Rush AJ, Mayberg HS, Craighead WE, and Kaddurah-Daouk R. Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Front NeuroSci; 2019; 13; 926. doi: http://doi.org/10.3389/fnins.2019.00926

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Trans Psychiatry; 2018; 8(1); doi: 10.1038/s41398-017-0056-8

Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P,  Tye SJ, Mayberg HS, Flavin DH, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW, and The Mood Disorders Precision Medicine Consortium (MDPMC). Mapping Depression Rating Scale Phenotypes onto Research Domain Criteria (RDoC) to Inform Biological Research in Mood Disorders. J Affect Disord; 2018; 238:1-7. doi: 10.1016/j.jad.2018.05.005

Athreya A, Iyer R, Neavin D, Wang L, Weinshilboum R, Kaddurah-Daouk R, Rush J, Frye M, Bobo W.
Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. IEEE Comput Intell Mag; 2018; 13(3): 20-31. doi: 10.1109/MCI.2018.2840660

Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM. Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochem Pharmacol. 2018 Jun;152:279-292. doi: 10.1016/j.bcp.2018.03.032. Epub 2018 Apr 3. PubMed PMID:29621538; PubMed Central PMCID: PMC5960634.

Fan TWM, Yuan P, Lane AN, Higashi RM, Wang Y, Hamidi AB, Zhou R, Guitart Z, Chen G, Manji HK, Kaddurah-Daouk R. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics; 2010; 6: 165-179.

Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng Z, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W. Cerebrospinal Fluid Metabolome in Mood Disorders. Science Reports; 2012;  2:667. doi: 10.1038.

Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E, Krishnan RR, Rush AJ, Pickering E, Delnomdedieu M. Pretreatment Metabotype as a Predictor of Response to Sertraline or Placebo in Depressed Outpatients: A Proof of Concept. Translational Psychiatry; 2011; Jul, 1 (7):  e26; doi:10.1038/tp.2011.22.

Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E, Wang Z, Rush AJ, Krishnan RR, Pickering E, Delnomdedieu M, Fiehn O. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry; 2013; 3:e223. doi: 10.1038/tp.2012.142.

Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M, Kaddurah-Daouk R, Network PR. (2013). Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder – possible role for methoxyindole pathway. PLoS One. 2013 Jul 17, 8(7):e68283. doi: 10.1371.

Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. ; 2011; 89(1):97-104.

Abo R, Hebbring S, Ji Y, Zhu H, Zeng ZB, Batzler A, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Fridley B, Schaid D, Kamatani N, Nakamura Y, Kubo M, Mushiroda T, Kaddurah-Daouk R, Mrazek DA, Weinshilboum RM. Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012; Apr;22(4):247-53.